461 related articles for article (PubMed ID: 16099324)
1. ApoE alleles and tau markers in patients with different levels of cognitive impairment.
Lavados M; Farías G; Rothhammer F; Guillon M; Mujica MC; Maccioni C; Maccioni RB
Arch Med Res; 2005; 36(5):474-9. PubMed ID: 16099324
[TBL] [Abstract][Full Text] [Related]
2. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
[TBL] [Abstract][Full Text] [Related]
3. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.
Herukka SK; Helisalmi S; Hallikainen M; Tervo S; Soininen H; Pirttilä T
Neurobiol Aging; 2007 Apr; 28(4):507-14. PubMed ID: 16546302
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment.
Buerger K; Teipel SJ; Zinkowski R; Sunderland T; Andreasen N; Blennow K; Ewers M; DeBernardis J; Shen Y; Kerkman D; Du Y; Hampel H
Neurosci Lett; 2005 Dec; 391(1-2):48-50. PubMed ID: 16165272
[TBL] [Abstract][Full Text] [Related]
6. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
7. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
8. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.
Devanand DP; Pelton GH; Zamora D; Liu X; Tabert MH; Goodkind M; Scarmeas N; Braun I; Stern Y; Mayeux R
Arch Neurol; 2005 Jun; 62(6):975-80. PubMed ID: 15956169
[TBL] [Abstract][Full Text] [Related]
9. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein E and alpha brain rhythms in mild cognitive impairment: a multicentric electroencephalogram study.
Babiloni C; Benussi L; Binetti G; Cassetta E; Dal Forno G; Del Percio C; Ferreri F; Ferri R; Frisoni G; Ghidoni R; Miniussi C; Rodriguez G; Romani GL; Squitti R; Ventriglia MC; Rossini PM
Ann Neurol; 2006 Feb; 59(2):323-34. PubMed ID: 16358334
[TBL] [Abstract][Full Text] [Related]
11. [Dementia and cognitive impairment pattern: its association with epsilon4 allele of apolipoprotein E gene].
Rosich-Estragó M; Figuera-Terré L; Mulet-Pérez B; Arrufat-Cardús MT; Pascual San Emeterio A; Arbeola-Rigau I; Labad-Alquézar A; Vilella-Cuadrada E
Rev Neurol; 2004 May 1-15; 38(9):801-7. PubMed ID: 15152345
[TBL] [Abstract][Full Text] [Related]
12. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.
Hoyt BD; Massman PJ; Schatschneider C; Cooke N; Doody RS
Arch Neurol; 2005 Mar; 62(3):454-9. PubMed ID: 15767511
[TBL] [Abstract][Full Text] [Related]
13. The effect of MAPT H1 and APOE ε4 on transition from mild cognitive impairment to dementia.
Samaranch L; Cervantes S; Barabash A; Alonso A; Cabranes JA; Lamet I; Ancín I; Lorenzo E; Martínez-Lage P; Marcos A; Clarimón J; Alcolea D; Lleó A; Blesa R; Gómez-Isla T; Pastor P
J Alzheimers Dis; 2010; 22(4):1065-71. PubMed ID: 20930301
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
Lane R; Feldman HH; Meyer J; He Y; Ferris SH; Nordberg A; Darreh-Shori T; Soininen H; Pirttilä T; Farlow MR; Sfikas N; Ballard C; Greig NH
Pharmacogenet Genomics; 2008 Apr; 18(4):289-98. PubMed ID: 18334913
[TBL] [Abstract][Full Text] [Related]
15. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment.
Caselli RJ; Reiman EM; Locke DE; Hutton ML; Hentz JG; Hoffman-Snyder C; Woodruff BK; Alexander GE; Osborne D
Arch Neurol; 2007 Sep; 64(9):1306-11. PubMed ID: 17846270
[TBL] [Abstract][Full Text] [Related]
16. Distribution of APOE genotypes in a memory clinic cohort.
van der Flier WM; Pijnenburg YA; Schoonenboom SN; Dik MG; Blankenstein MA; Scheltens P
Dement Geriatr Cogn Disord; 2008; 25(5):433-8. PubMed ID: 18401171
[TBL] [Abstract][Full Text] [Related]
17. Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations.
Fabre SF; Forsell C; Viitanen M; Sjögren M; Wallin A; Blennow K; Blomberg M; Andersen C; Wahlund LO; Lannfelt L
Exp Neurol; 2001 Apr; 168(2):413-8. PubMed ID: 11259129
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E genotypes in hospitalized elderly patients with vascular dementia.
Orsitto G; Seripa D; Panza F; Franceschi M; Cascavilla L; Placentino G; Matera MG; Paris F; Capurso C; Solfrizzi V; Dallapiccola B; Pilotto A
Dement Geriatr Cogn Disord; 2007; 23(5):327-33. PubMed ID: 17374951
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E polymorphism and brain morphology in mild cognitive impairment.
Thomann PA; Roth AS; Dos Santos V; Toro P; Essig M; Schröder J
Dement Geriatr Cogn Disord; 2008; 26(4):300-5. PubMed ID: 18843182
[TBL] [Abstract][Full Text] [Related]
20. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
